Last reviewed 2026-04-22 · How we verify

Belatacept LI (less intensive)

Belatacept is a selective T-cell costimulation blocker that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells.

Belatacept is a selective T-cell costimulation blocker that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells. Used for Prevention of organ rejection in kidney transplant recipients.

At a glance

Mechanism of action

Belatacept is a fusion protein (CTLA4-Ig) that blocks the CD28-mediated costimulatory signal required for full T-cell activation. By preventing the interaction between CD28 on T cells and CD80/CD86 on antigen-presenting cells, it suppresses T-cell proliferation and cytokine production. The 'LI' (less intensive) formulation refers to a reduced-dosing regimen designed to maintain efficacy while minimizing immunosuppression.

Approved indications

• Prevention of organ rejection in kidney transplant recipients

Common side effects

• Infection (including CMV, BK virus)
• Malignancy
• Acute rejection
• Hypertension
• Diarrhea

Key clinical trials

• Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant (PHASE3)
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) (PHASE3)
• Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney (PHASE2)
• Belatacept in Liver Transplant Recipients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Belatacept LI (less intensive) CI brief — competitive landscape report
• Belatacept LI (less intensive) updates RSS · CI watch RSS
• Bristol-Myers Squibb portfolio CI